Biodel To Report Results Of VIAject? Pivotal Phase III Clinical Trials At EASD Conference

Biodel Inc. (Nasdaq: BIOD) announced that it will report results of its two pivotal Phase III clinical trials of VIAject? in patients with Type 1 and Type 2 diabetes next week at the 44th Annual Meeting of the European Association for the Study of Diabetes in Rome. Two posters summarizing these results, #677 by Flacke et al.

More: continued here

Filed under: Diabetes on September 8th, 2008